Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.76 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.76 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.76 |
| ▸ | RAF1 | P04049 | 10/20 | 0.76 |
| ▸ | BRAF | P15056 | 6/20 | 0.76 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.76 |
| ▸ | GCGR | P47871 | 4/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511391 | 1.00 | ALOX5 (0.79) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25008485 | 0.93 | ALOX5 (0.67) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6465062 | 0.88 | ALOX5 (1.00) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4553281 | 0.88 | ALOX5 (1.00) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2949385 | 0.87 | MAPK13 (1.00) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7228717 | 0.87 | MAPK13 (1.00) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16497639 | 0.85 | MAPK14 (0.83) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16510932 | 0.84 | BRAF (0.68) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16510921 | 0.83 | BRAF (0.75) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL19868929 | 0.83 | MAPK13 (0.71) | ALOX5MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | ALOX5 2555/4885MAPK13 2219/4885MAPK12 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.